2012

New therapeutic pathways in the RAS.
Bader, M. ORCID: https://orcid.org/0000-0003-4780-4164, Santos, R.A. ORCID: https://orcid.org/0000-0001-8738-5852, Unger, T. and Steckelings, U.M.
Journal of the Renin Angiotensin Aldosterone System 13 (4): 505-508. December 2012

2011

Vitamin D review.
Mueller, D.N. ORCID: https://orcid.org/0000-0003-3650-5644, Kleinewietfeld, M. ORCID: https://orcid.org/0000-0002-2832-3149 and Kvakan, H.
Journal of the Renin Angiotensin Aldosterone System 12 (2): 125-128. June 2011

2010

The past, present and future of angiotensin II type 2 receptor stimulation.
Steckelings, U.M., Rompe, F., Kaschina, E., Namsolleck, P., Grzesiak, A., Funke-Kaiser, H., Bader, M. ORCID: https://orcid.org/0000-0003-4780-4164 and Unger, T.
Journal of the Renin Angiotensin Aldosterone System 11 (1): 67-73. March 2010

2008

Renin-angiotensin system-related highlights from the High Blood Pressure Research Conference annual meeting.
Luft, F.C. ORCID: https://orcid.org/0000-0002-8635-1199
Journal of the Renin Angiotensin Aldosterone System 9 (4): 242-247. December 2008

Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz, R., Dechend, R. ORCID: https://orcid.org/0000-0001-6636-3080, Yu, C.M., Bheda, M., Ford, J., Prescott, M.F. and Keefe, D.L.
Journal of the Renin Angiotensin Aldosterone System 9 (3): 163-175. September 2008

The Bothrops legacy: Vasoactive peptides from Brazil.
Luft, F.C. ORCID: https://orcid.org/0000-0002-8635-1199
Journal of the Renin Angiotensin Aldosterone System 9 (1): 57-64. 1 March 2008

2007

The second life of the (pro)renin receptor.
Bader, M. ORCID: https://orcid.org/0000-0003-4780-4164
Journal of the Renin Angiotensin Aldosterone System 8 (4): 205-208. December 2007

Spotlight on renin. Mechanisms of hypertension-induced target organ damage.
Mueller, D.N. ORCID: https://orcid.org/0000-0003-3650-5644
Journal of the Renin Angiotensin Aldosterone System 8 (3): 148-150. September 2007

Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes.
Dechend, R. ORCID: https://orcid.org/0000-0001-6636-3080, Shagdarsuren, E., Gratze, P., Fiebeler, A., Pilz, B., Meiners, S., Derer, W., Feldman, D.L., Webb, R. and Mueller, D.N. ORCID: https://orcid.org/0000-0003-3650-5644
Journal of the Renin Angiotensin Aldosterone System 8 (2): 81-84. June 2007

2006

Achieving the goal of optimised renin system suppression: preclinical experience with a direct renin inhibitor.
Luft, F.C. ORCID: https://orcid.org/0000-0002-8635-1199
Journal of the Renin Angiotensin Aldosterone System 7 (Suppl 2): S12-S15. December 2006

2003

Telmisartan effectiveness on left ventricular MAss reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension - a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months - rationale and study design.
Friedrich, M.G., Dahlof, B., Sechtem, U., Unger, T., Knecht, M. and Dietz, R.
Journal of the Renin Angiotensin Aldosterone System 4 : 234-243. 1 January 2003

2000

Neurohumoral blockade in CHF management.
Willenbrock, R., Philipp, S., Mitrovic, V. and Dietz, R.
Journal of the Renin Angiotensin Aldosterone System 1 (Suppl 1): 24-30. September 2000